Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces website-transition updates and a shift in terminology from “Artificial Intelligence” to “Super Intelligence.” The clinical-trial record still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-20T18:49:12.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T19:53:35.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    Access to the study page now returns a 403 Forbidden error, displaying a 403 header and a Home link instead of the study details. The previous study content appears to be inaccessible on this page.
    Difference
    22%
    Check dated 2026-09-22T21:00:12.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    A new page revision label 'Revision: v3.7.0' is now displayed, indicating an update to the page version. The old revision label 'Revision: v3.6.6' and related topics such as 'Melanoma' and 'MedlinePlus Genetics' were removed.
    Difference
    0.2%
    Check dated 2026-09-15T20:53:04.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The study record adds posted results and a new Phase II description with expanded endpoints and timing for efficacy measurements (e.g., ORR, PFS, PD-1/LAG-3 expression, and tumor assessments).
    Difference
    9%
    Check dated 2026-09-01T17:58:52.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The related topics section now lists Melanoma and MedlinePlus Genetics. This is a navigational/content enhancement that helps users connect the study with its disease context and genetics resources without changing any trial data.
    Difference
    0.2%
    Check dated 2026-08-25T16:37:48.000Z thumbnail image

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.